[Therapeutic effect of Chinese medicinal herbs combined with chemotherapy on advanced non-small cell lung cancer]

Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997 Jan;17(1):26-8.
[Article in Chinese]

Abstract

Objective: To observe the effect of Chinese medicinal herbs (CMH) and chemotherapy on non-small cell lung cancer.

Methods: Comparing the therapeutic effects of three treatment regimens on 58 advanced non-small cell lung cancer (NSCLC) patients who were treated with CMH plus chemotherapy (CT), 28 cases treated with CT only, and 24 cases treated with CMH alone.

Results: Effective rates (partial remission + complete remission) were 22.9% in CMH + CT group, 13.6% both in CT and in CMH group. There were no significant differences between these three groups according to the short-term results (P > 0.05). Mean survival time (month) for CMH + CT, CT and CMH groups were 10.2, 5.3 and 8.0 respectively. The survival rate (Kaplan Meicr method) of both CMH + CT and CMH group were significantly higher than that of CT group (P < 0.01, P < 0.05) but no significant difference between CMH and CMH + CT group (P > 0.05).

Conclusion: Chinese medicinal herbs were helpful to improve median survival time and survival rate of patients with advanced NSCLC.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Therapy, Combination
  • Drugs, Chinese Herbal / therapeutic use*
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Survival Rate

Substances

  • Drugs, Chinese Herbal
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin

Supplementary concepts

  • CISCA protocol
  • EAP protocol
  • VP-P protocol